Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Insulin Glargine As Effective As NPH Insulin In Achieving Glycemic Control In Type I Diabetes: Presented at EASD

        By Emma Hitt
        Special to DG News

        BUDAPEST, HUNGARY -- September 2, 2002 -- Insulin glargine appears to be equivalent to, if not more effective than, neutral protamine Hagedorn (NPH) insulin in improving HbA1c and fasting blood glucose (FBG) levels among patients with type I diabetes.
        Insulin glargine is a long-acting recombinant human insulin analog indicated for type I and type 2 diabetics. A once-daily injection is thought to minimize hypoglycemia because of its prolonged absorption profile.

        Findings of two randomized trials were presented today (September 2) during the European Association for the Study of Diabetes (EASD) meeting, in Budapest, Hungary.

        In one study, Dr. Greg Fulcher with the Royal North Shore Hospital, St Leonard's, New South Wales, Australia, and colleagues randomized 49 male and 76 female patients with poorly controlled type I diabetes (HbA1c greater than 8.0 percent) to receive either insulin glargine or NPH insulin at bedtime for 30 weeks.

        Patient satisfaction was evaluated using a diabetes treatment satisfaction questionnaire, and severity of hypoglycemic events was classified as mild, moderate, and severe using predetermined criteria.

        By the end of the study, HbA1c was reduced significantly in patients receiving insulin glargine compared to those receiving NPH insulin (8.43 percent ± 0.14 percent versus 8.96 percent ± 0.14 percent p=0.01). Similarly, average FBG was 1.19 mM (21.42 mg/dL) lower in the insulin glargine group compared to the NPH insulin group (p<0.05).

        Fewer moderate and severe nocturnal hypoglycemic episodes were observed in the insulin glargine group compared to the NPH group, Dr. Fulcher and colleagues report.

        At the same session, Dr. Philip Home, with the University of Newcastle upon Tyne, England, and colleagues presented their research, also comparing insulin glargine with NPH insulin in adults with Type 1 diabetes.

        A total of 585 patients with type 1 diabetics were randomized to receive once-daily insulin glargine at bedtime, or once- or twice-daily NPH insulin for 28 weeks.

        Baseline to endpoint change in FBG and HbA1c were similar between the insulin glargine and NPH insulin treatment groups. However, in patients who had been on a twice-daily basal insulin regimen before the study, "there was a clinically relevant decrease in FBG" in the glargine compared to NPH groups, they report. However, hypoglycemic episodes appeared to be similar in number and severity between the treatment groups.

        "The National Institute for Clinical Excellence (NICE) are currently reviewing insulin glargine, and will be issuing guidance on its use over the next 4 months," Dr. Home told Doctor's Guide.

        Both studies were funded by Aventis pharmaceuticals.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send